Croatia, Zagreb, June 29 , 201 8 Ljiljana Sović Brkičić

1. The Pharmaceutical Composition Technology enables controlled concentration of drug in blood Croatia, Zagreb, June 29, 2018 Ljiljana Sović Brkičić

2. Company Purpose BLC pharmaceutica d.o.o. BLC pharmaceutica is a small R&D company Vision… to be important subject in the R&D Mission … to find better solution, to manage idaes to…

3. Problem & Solution

4. Value Proposition Users Benefits Patients • better drug treatments • better therapy • better quality of life  • therapeutic – lower side effects • economic – saving money • business – staying on job / working Health insurances / payers • will ensure better treatments • rationalisation of costs • lower costs  • therapeutic – better healthcare • economic - saving money (long-term) • business – better results Pharmaceutical company • will produce better products • good business opportunity • higher market share  • added value – higher profit • revenues in billion / blockbusters • The Platform

5. Market Opportunity & Risks Market European and global Blockbusters (past and future) Revenues in billion / PH company The Platform Usable to all drugs containing N (nitrogen)

6. Competition Example - novel levodopa (antiparkisonic) Competitors Duodopa Existing oral formulations Novel formulation Price per year 50,000 Euros or more 1,000 Euros 3,000 - 5,000 Euros Administration parenteral oral oral Features unacceptable application causes side effects well controlled release Rating of CR excellent bad very good Expensive Very inconvenient Highly effective Low cost Convenient Ineffective Price acceptable Convenient Very Effective Evaluation

7. Business Model § Licensing (Model 1 of commercialization) • cooperation with big pharmaceutical company (Big PH) • resources, fast model, revenues - up front fee, royalty • revenues in billion (Big PH), in million (SME) Production (Model 2 ofcommercialization) • outsourced production, laterownproduction • higher costs, slower realization, longerexploitation Next proceedings • completing of package for commercialization / licensing • smalltrials (knownmainandadditonalsubstances)

8. Commercialization & Marketing …to Big PH company • crisis in PH industry • lack of good inventions • need for novel products • Big PH likes „Platforms” • commercialization – 3st year …outsourced production • finalization of R&D • small trials • need for better therapy • registration of medicines • commercialization – 3rd year Licensing (Model 1)… Production (Model 2)…

9. Financial Projections Big PH (Model 1) • will conduct marketing • resource, network • production - blockbusters • EU funds– pilot study • future – Model 3 SME (Model 2) • will conduct marketing • need – patients, wholesales • investment – 1,5M Euros • EU funds - commercialization • future – R&D / novel products Licensing… Production…

10. Who we are? ? Zdravko Dokuzović, PhD Researcher, inventor, technologist, earlier patents Ljiljana Sović Brkičić Researcher, inventor, patent applicant, idea, business strategy Cvjetko Brkičić Patent applicant, business experience, investment - 1,000,000 € Team – 95 years of experience; 9 years on this project;36,500 hours ofwork (this project) BLC pharmaceutica d.o.o. Croatia, Zagreb, Kralja Zvonimira 82 http://www.pharmaceutica.blc.hr/ • Ljiljana Sović Brkičić • ljiljana.sovic@gmail.com • pharmaceutica@blc.hr